pear-20220328


Delaware	001-39969	85-4103092
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
200 State Street, 13th Floor Boston, MA 02109
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (617) 925-7848

Not Applicable
	(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class A common stock,
par value $.0001 per share

PEAR

The Nasdaq Stock Market LLC

Warrants, each exercisable for
one share of Class A common stock
for $11.50 per share

PEARW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Pear Therapeutics, Inc. with the Securities and Exchange Commission on March 28, 2022 (the “Original Form 8-K”) in which Item 2.02, which was included in the Original Form 8-K, was inadvertently not tagged in the Original Form 8-K. This Form 8-K/A is being filed solely for the purpose of fixing the tagging. Except as provided herein, the Original Form 8-K remains unchanged.

On March 28, 2022, Pear Therapeutics, Inc. (the Company) issued a press release reporting the financial results of the Company for its year ended December 31, 2021. A copy of the press release is attached to this Current Report as Exhibit 99.1.

The information in this Current Report, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.



Exhibit No.						Description

99.1						Press Release of Pear Therapeutics, Inc. dated March 28, 2022.
104						Inline XBRL for the cover page of this Current Report on Form 8-K.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Pear Therapeutics, Inc.

By:						/s/ Christopher D.T. Guiffre
Name:						Christopher D.T. Guiffre, J.D., M.B.A.
Title:						Chief Financial Officer & Chief Operating Officer